In agreement, several studies report that anti-Gal1 monoclonal antibody (mAb) treatment in experimental tumor models provides a therapeutic benefit without apparent side effects [6, 7, 18, 19], confirming Gal1 as a highly interesting target in tumor therapy. This evidence concerns the gene GAL and neoplasm.